Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

NCT00523380 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Ovarian Cancer

Interventions

DRUG: recombinant interleukin-21
DRUG: caelyx (pegylated liposomal doxorubicin)

Sponsor

Novo Nordisk A/S